CN100428936C - 抗病毒化合物 - Google Patents

抗病毒化合物 Download PDF

Info

Publication number
CN100428936C
CN100428936C CNB028099044A CN02809904A CN100428936C CN 100428936 C CN100428936 C CN 100428936C CN B028099044 A CNB028099044 A CN B028099044A CN 02809904 A CN02809904 A CN 02809904A CN 100428936 C CN100428936 C CN 100428936C
Authority
CN
China
Prior art keywords
ester
virus
purposes
octahydro
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028099044A
Other languages
English (en)
Chinese (zh)
Other versions
CN1516582A (zh
Inventor
A·S·蒂姆斯
D·L·泰勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Sanofi Aventis France
Original Assignee
Virogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogen Ltd filed Critical Virogen Ltd
Publication of CN1516582A publication Critical patent/CN1516582A/zh
Application granted granted Critical
Publication of CN100428936C publication Critical patent/CN100428936C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CNB028099044A 2001-05-03 2002-05-02 抗病毒化合物 Expired - Lifetime CN100428936C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110832.3A GB0110832D0 (en) 2001-05-03 2001-05-03 Antiviral compounds
GB0110832.3 2001-05-03

Publications (2)

Publication Number Publication Date
CN1516582A CN1516582A (zh) 2004-07-28
CN100428936C true CN100428936C (zh) 2008-10-29

Family

ID=9913938

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028099044A Expired - Lifetime CN100428936C (zh) 2001-05-03 2002-05-02 抗病毒化合物

Country Status (19)

Country Link
US (1) US7601735B2 (enExample)
EP (1) EP1387681B1 (enExample)
JP (2) JP2004527566A (enExample)
KR (1) KR100660241B1 (enExample)
CN (1) CN100428936C (enExample)
AT (1) ATE405261T1 (enExample)
AU (1) AU2002341155B2 (enExample)
CA (1) CA2445271A1 (enExample)
CY (1) CY1110437T1 (enExample)
DE (1) DE60228436D1 (enExample)
DK (1) DK1387681T3 (enExample)
ES (1) ES2312587T3 (enExample)
GB (1) GB0110832D0 (enExample)
IL (2) IL158558A0 (enExample)
NO (1) NO326292B1 (enExample)
NZ (1) NZ529448A (enExample)
PT (1) PT1387681E (enExample)
WO (1) WO2002089780A2 (enExample)
ZA (1) ZA200308483B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
EA200700718A1 (ru) * 2004-10-06 2007-12-28 Мидженикс Инк. Комбинированные противовирусные композиции, содержащие кастаноспермин, и способы их применения
WO2006096285A2 (en) * 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
JP2007297289A (ja) * 2006-04-27 2007-11-15 Kitasato Gakuen 抗ウイルス剤
EP2054076A2 (en) * 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
KR101314166B1 (ko) * 2011-06-16 2013-10-04 건국대학교 산학협력단 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
MX378015B (es) * 2013-03-15 2025-03-10 60 Pharmaceuticals Llc Nuevos regímenes de dosificación de celgosivir para el tratamiento de dengue.
UA117499C2 (uk) * 2013-09-27 2018-08-10 Мерк Шарп Енд Доум Корп. Заміщені похідні хінолізину, які можна використовувати як інгібітори інтегрази віл
US10046005B2 (en) * 2014-02-07 2018-08-14 Shaker A. Mousa Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AU2016368580B2 (en) * 2015-12-11 2021-08-19 60 Degrees Pharmaceuticals, Inc. Novel dosing regimens of celgosivir for the prevention of dengue
DK3436435T3 (da) 2016-03-31 2021-08-09 Janssen Pharmaceuticals Inc Substituerede indolderivater som inhibitorer af replikation af denguevirus
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3013408A1 (en) 2016-04-01 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HUE054379T2 (hu) 2017-05-22 2021-09-28 Janssen Pharmaceuticals Inc Helyettesített indolin-származékok mint a dengue vírus szaporodásának inhibitorai
WO2018215315A1 (en) 2017-05-22 2018-11-29 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び／又は予防剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029321A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315276C (en) 1987-07-02 1993-03-30 Paul S. Liu Castanospermine esters and glycosides
US5004746A (en) * 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4849430A (en) * 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4970317A (en) * 1989-08-08 1990-11-13 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine esters
US5066807A (en) * 1990-03-12 1991-11-19 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine
US5093501A (en) * 1990-03-12 1992-03-03 Merrell Dow Pharmaceuticals Inc. Intermediates in a process for the preparation of castanospermine
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US5959111A (en) * 1997-05-22 1999-09-28 Hoechst Marion Roussel, Inc. Process for preparing 6-0-monoesters of castanospermine
AU2001234596A1 (en) * 2000-01-28 2001-08-07 Timothy M Block Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
WO1999029321A1 (en) * 1997-12-11 1999-06-17 The Chancellor, Masters And Scholars Of The University Of Oxford Inhibition of membrane-associated viral replication

Also Published As

Publication number Publication date
HK1068538A1 (zh) 2005-04-29
ZA200308483B (en) 2005-10-26
JP4406383B2 (ja) 2010-01-27
WO2002089780A2 (en) 2002-11-14
EP1387681B1 (en) 2008-08-20
PT1387681E (pt) 2008-12-02
NO20034878D0 (no) 2003-10-31
US20040147549A1 (en) 2004-07-29
CN1516582A (zh) 2004-07-28
EP1387681A2 (en) 2004-02-11
NO20034878L (no) 2003-12-22
CY1110437T1 (el) 2015-04-29
KR20040007527A (ko) 2004-01-24
AU2002341155B2 (en) 2007-10-18
DK1387681T3 (da) 2009-01-05
IL158558A0 (en) 2004-05-12
KR100660241B1 (ko) 2006-12-20
US7601735B2 (en) 2009-10-13
ES2312587T3 (es) 2009-03-01
DE60228436D1 (de) 2008-10-02
WO2002089780A3 (en) 2003-03-06
JP2005290015A (ja) 2005-10-20
JP2004527566A (ja) 2004-09-09
IL158558A (en) 2011-09-27
NZ529448A (en) 2005-11-25
NO326292B1 (no) 2008-11-03
CA2445271A1 (en) 2002-11-14
GB0110832D0 (en) 2001-06-27
ATE405261T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
CN100428936C (zh) 抗病毒化合物
EP1200091B1 (en) Pharmaceutical composition comprising tadalafil
TW200412960A (en) Potent inhibitor of HCV serine protease
JP2014141506A (ja) デングウイルス感染を治療及び予防するためのチエノピリジン誘導体類
CN101448497A (zh) 病毒性肝炎治疗
AU2002341155A1 (en) Antiviral compounds
CA2481092A1 (en) Low dose liquid entecavir formulations and use
JPH07507770A (ja) Ｎ−（ホスホノアセチル）−ｌ−アスパラギン酸組成物，および広域抗ウイルス剤としてのその使用方法
PL190505B1 (pl) Kompozycja farmaceutyczna i sposób jej wytwarzania
HU210257B (en) Process for the preparation of pharmaceutical composition with anti-herpes effect containing castanospermine esters
JPS6256425A (ja) マラリア治療用の組合せ製剤
CN103421068A (zh) 具有抗病毒活性的杂芳基磷酰胺类化合物
JPWO2009054401A1 (ja) 複素芳香族化合物を有効成分とする抗ウイルス剤
Jabeen et al. A review on the antiparasitic drug ivermectin for various viral infections and possibilities of using it for novel severe acute respiratory syndrome coronavirus 2: New hope to treat coronavirus disease-2019
CN118772098B (zh) 一类具有抗炎保肝活性呋喃类化合物、其制备及用途
HK1068538B (en) Antiviral compounds
CN111067898B (zh) 盐酸小檗碱在水产养殖中抗鲤疱疹病毒ⅱ型的用途
CN115957303B (zh) 蛇毒多肽Hc-CATH在制备防治寨卡病毒感染的药物中的应用
JPWO1997030706A1 (ja) 抗腫瘍剤含有組成物
CN118178362A (zh) 2,2'-（2-亚甲基丙烷-1,3-二基）双（4-异丙基苯酚）在制备nlrp3炎性小体抑制剂中的应用
CN119587555A (zh) 依碳氯替泼诺作为nlrp3炎症小体激活抑制剂的用途
KR100293299B1 (ko) 레트로비루스억제제배합물
CN118370833A (zh) Sting激动剂在制备抑制猴痘病毒的药物中的应用
CN117618440A (zh) 一种头孢拉定一水合物在制备抗顺铂耳毒性药物中的应用
CN120960185A (zh) 麝香酮在制备病毒抑制剂中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068538

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1068538

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SANOFI SYNTHELABO

Free format text: FORMER OWNER: VIROGEN LTD.

Effective date: 20120912

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: SANOFI

Free format text: FORMER NAME: SANOFI SYNTHELABO

CP01 Change in the name or title of a patent holder

Address after: Paris France

Patentee after: Sanofi

Address before: Paris France

Patentee before: SANOFI-AVENTIS

TR01 Transfer of patent right

Effective date of registration: 20120912

Address after: Paris France

Patentee after: SANOFI-AVENTIS

Address before: London, England

Patentee before: Virogen Ltd.

CX01 Expiry of patent term

Granted publication date: 20081029

CX01 Expiry of patent term